4-(5-(2-CHLOROPHENYL)-4H-1,2,4-TRIAZOL-3-YL)PYRIDINE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HMAFBPXQCCSYQV-UHFFFAOYSA-N
Smiles	Clc1ccccc1c2nnc([nH]2)c3ccncc3
InChI	InChI=1S/C13H9ClN4/c14-11-4-2-1-3-10(11)13-16-12(17-18-13)9-5-7-15-8-6-9/h1-8H,(H,16,17,18)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H9ClN4
Molecular Weight	256.69
AlogP	2.56
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	2.0
Polar Surface Area	54.46
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	18.0

Assay Description	Organism	Bioactivity
Analgesic activity in Mus musculus albino (mouse) assessed as inhibition of formalin-induced paw licking behavior in both phases of formalin response at 25 mg/kg, ip administered 30 min before formalin challenge	Mus musculus	None
Analgesic activity in Mus musculus albino (mouse) assessed as latency time at 25 mg/kg, ip after 30 min by hot-plate test	Mus musculus	13.12 s
Analgesic activity in Mus musculus albino (mouse) assessed as latency time at 25 mg/kg, ip after 30 min in presence of 2 mg/kg, ip of mecamylamine by tail-flick test	Mus musculus	5.12 s
Analgesic activity in Mus musculus albino (mouse) assessed as latency time at 25 mg/kg, ip after 30 min by tail-flick test	Mus musculus	11.2 s

Cross References

Resources	Reference
ChEMBL	CHEMBL2261817
PubChem	4730444

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).